SK6252002A3 - Treatment of viral infections using levovirintm - Google Patents

Treatment of viral infections using levovirintm Download PDF

Info

Publication number: SK6252002A3
Authority: SK; Slovakia
Prior art keywords: increase; response; value; average peak; weight
Prior art date: 1999-12-23

Application number

SK625-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Robert Tam

Original Assignee

Icn Pharmaceuticals

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-23

Filing date

2000-12-15

Publication date

2003-02-04

2000-12-15 Application filed by Icn Pharmaceuticals filed Critical Icn Pharmaceuticals

2003-02-04 Publication of SK6252002A3 publication Critical patent/SK6252002A3/sk

Links

208000036142 Viral infection Diseases 0.000 title claims abstract description 23
230000009385 viral infection Effects 0.000 title claims abstract description 23
208000015181 infectious disease Diseases 0.000 claims abstract description 7
208000031886 HIV Infections Diseases 0.000 claims abstract description 4
208000037357 HIV infectious disease Diseases 0.000 claims abstract description 4
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 4
230000004044 response Effects 0.000 claims description 36
102000004127 Cytokines Human genes 0.000 claims description 35
108090000695 Cytokines Proteins 0.000 claims description 35
108010074328 Interferon-gamma Proteins 0.000 claims description 13
102100037850 Interferon gamma Human genes 0.000 claims description 12
108010002350 Interleukin-2 Proteins 0.000 claims description 12
102000000588 Interleukin-2 Human genes 0.000 claims description 12
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 12
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 11
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 9
150000001875 compounds Chemical class 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 2
238000001727 in vivo Methods 0.000 claims description 2
238000000034 method Methods 0.000 abstract description 21
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical class N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 30
229960000329 ribavirin Drugs 0.000 description 28
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 28
IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 description 19
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 16
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
230000000694 effects Effects 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
230000000840 anti-viral effect Effects 0.000 description 13
241000725303 Human immunodeficiency virus Species 0.000 description 10
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000000047 product Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
229960003180 glutathione Drugs 0.000 description 8
235000019439 ethyl acetate Nutrition 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
239000011701 zinc Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
108010082126 Alanine transaminase Proteins 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
241000700605 Viruses Species 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
239000000203 mixture Substances 0.000 description 6
108010053070 Glutathione Disulfide Proteins 0.000 description 5
208000002606 Paramyxoviridae Infections Diseases 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
239000000243 solution Substances 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
241000725643 Respiratory syncytial virus Species 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000013078 crystal Substances 0.000 description 4
230000003013 cytotoxicity Effects 0.000 description 4
231100000135 cytotoxicity Toxicity 0.000 description 4
230000028993 immune response Effects 0.000 description 4
230000036039 immunity Effects 0.000 description 4
206010022000 influenza Diseases 0.000 description 4
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
230000008569 process Effects 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
108010062580 Concanavalin A Proteins 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
108010065805 Interleukin-12 Proteins 0.000 description 3
102000013462 Interleukin-12 Human genes 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229910000831 Steel Inorganic materials 0.000 description 3
239000012300 argon atmosphere Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000012267 brine Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
230000016396 cytokine production Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000000284 extract Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
230000007774 longterm Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000010959 steel Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
230000029812 viral genome replication Effects 0.000 description 3
KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
206010061818 Disease progression Diseases 0.000 description 2
208000005176 Hepatitis C Diseases 0.000 description 2
108090000174 Interleukin-10 Proteins 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
108010002616 Interleukin-5 Proteins 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
210000000447 Th1 cell Anatomy 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
230000036436 anti-hiv Effects 0.000 description 2
230000002155 anti-virotic effect Effects 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000005750 disease progression Effects 0.000 description 2
239000002024 ethyl acetate extract Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
230000002949 hemolytic effect Effects 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
239000002955 immunomodulating agent Substances 0.000 description 2
229940121354 immunomodulator Drugs 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
201000002364 leukopenia Diseases 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
230000001629 suppression Effects 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
-1 1- (5-deoxy-D-ribofuranosyl) -1,2,4-triazole- 3-carboxamide Chemical compound 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
206010015719 Exsanguination Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108090000176 Interleukin-13 Proteins 0.000 description 1
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
108010002335 Interleukin-9 Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
210000004241 Th2 cell Anatomy 0.000 description 1
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
239000013566 allergen Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000003914 blood derivative Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002026 chloroform extract Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000531 effect on virus Effects 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000010710 hepatitis C virus infection Diseases 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000037797 influenza A Diseases 0.000 description 1
208000037798 influenza B Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
229940117681 interleukin-12 Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
QMPFMODFBNEYJH-UHFFFAOYSA-N methyl 1h-1,2,4-triazole-5-carboxylate Chemical compound COC(=O)C1=NC=NN1 QMPFMODFBNEYJH-UHFFFAOYSA-N 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
229940127073 nucleoside analogue Drugs 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002688 persistence Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
238000007859 qualitative PCR Methods 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/044—Pyrrole radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Oncology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

SK625-2002A 1999-12-23 2000-12-15 Treatment of viral infections using levovirintm SK6252002A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/471,513 US6518253B1 (en)	1999-11-19	1999-12-23	Treatment of viral infections using the L-isomer of ribavirin
PCT/US2000/034610 WO2001046212A1 (en)	1999-12-23	2000-12-15	Treatment of viral infections using levovirin?tm¿

Publications (1)

Publication Number	Publication Date
SK6252002A3 true SK6252002A3 (en)	2003-02-04

Family

ID=23871906

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK625-2002A SK6252002A3 (en)	1999-12-23	2000-12-15	Treatment of viral infections using levovirintm

Country Status (22)

Country	Link
US (2)	US6518253B1 (pl)
EP (1)	EP1246832A1 (pl)
JP (1)	JP2003518134A (pl)
KR (1)	KR20030016213A (pl)
CN (1)	CN1409721A (pl)
AU (1)	AU2281601A (pl)
BR (1)	BR0016163A (pl)
CA (1)	CA2384110A1 (pl)
CZ (1)	CZ2002968A3 (pl)
HK (1)	HK1050011A1 (pl)
HR (1)	HRP20020486A2 (pl)
HU (1)	HUP0400500A2 (pl)
IL (1)	IL148510A0 (pl)
MX (1)	MXPA02006259A (pl)
NO (1)	NO20022816L (pl)
PL (1)	PL356640A1 (pl)
RU (1)	RU2002112248A (pl)
SI (1)	SI21042A (pl)
SK (1)	SK6252002A3 (pl)
WO (1)	WO2001046212A1 (pl)
YU (1)	YU47702A (pl)
ZA (1)	ZA200202739B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7638496B2 (en)	2000-02-15	2009-12-29	Valeant Pharmaceuticals North America	Nucleoside analogs with carboxamidine modified monocyclic base
JP2004533406A (ja)	2000-10-18	2004-11-04	フアーマセツト・リミテツド	ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド
JP2005539032A (ja) *	2002-08-12	2005-12-22	エフ．ホフマン−ラ　ロシュ　アーゲー	リボフラノースの製造方法
WO2004052905A2 (en) *	2002-12-10	2004-06-24	F. Hoffmann-La Roche Ag	Antiviral nucleoside derivatives
US7125853B2 (en) *	2003-01-07	2006-10-24	Kemin Pharma B.V.B.A.	Bicyclic carbohydrate compounds useful in the treatment of infections caused by Flaviviridae sp., such as hepatitis C and bovine viral diarrhea viruses
US20050009848A1 (en) *	2003-07-10	2005-01-13	Icn Pharmaceuticals Switzerland Ltd.	Use of antivirals against inflammatory bowel diseases
US6930093B2 (en) *	2003-07-10	2005-08-16	Valeant Research & Development	Use of ribofuranose derivatives against inflammatory bowel diseases
US20050182252A1 (en)	2004-02-13	2005-08-18	Reddy K. R.	Novel 2'-C-methyl nucleoside derivatives
US20140010783A1 (en) *	2012-07-06	2014-01-09	Hoffmann-La Roche Inc.	Antiviral compounds
US10449210B2 (en)	2014-02-13	2019-10-22	Ligand Pharmaceuticals Inc.	Prodrug compounds and their uses
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途
CN111788196A (zh)	2018-01-09	2020-10-16	配体药物公司	缩醛化合物及其治疗用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6150337A (en) *	1996-01-23	2000-11-21	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
AU738170B2 (en) *	1996-10-16	2001-09-13	Icn Pharmaceuticals, Inc.	Monocyclic L-nucleosides, analogs and uses thereof

1999
- 1999-12-23 US US09/471,513 patent/US6518253B1/en not_active Expired - Lifetime
2000
- 2000-12-15 KR KR1020027008071A patent/KR20030016213A/ko not_active Withdrawn
- 2000-12-15 RU RU2002112248/14A patent/RU2002112248A/ru unknown
- 2000-12-15 BR BR0016163-2A patent/BR0016163A/pt not_active IP Right Cessation
- 2000-12-15 PL PL00356640A patent/PL356640A1/pl not_active Application Discontinuation
- 2000-12-15 AU AU22816/01A patent/AU2281601A/en not_active Abandoned
- 2000-12-15 HR HR20020486A patent/HRP20020486A2/hr not_active Application Discontinuation
- 2000-12-15 US US10/168,941 patent/US20030092644A1/en not_active Abandoned
- 2000-12-15 CN CN00817021A patent/CN1409721A/zh active Pending
- 2000-12-15 HK HK03102256.2A patent/HK1050011A1/zh unknown
- 2000-12-15 YU YU47702A patent/YU47702A/sh unknown
- 2000-12-15 CA CA002384110A patent/CA2384110A1/en not_active Abandoned
- 2000-12-15 SI SI200020046A patent/SI21042A/sl not_active IP Right Cessation
- 2000-12-15 CZ CZ2002968A patent/CZ2002968A3/cs unknown
- 2000-12-15 JP JP2001547121A patent/JP2003518134A/ja active Pending
- 2000-12-15 MX MXPA02006259A patent/MXPA02006259A/es unknown
- 2000-12-15 SK SK625-2002A patent/SK6252002A3/sk not_active Application Discontinuation
- 2000-12-15 IL IL14851000A patent/IL148510A0/xx unknown
- 2000-12-15 WO PCT/US2000/034610 patent/WO2001046212A1/en not_active Ceased
- 2000-12-15 HU HU0400500A patent/HUP0400500A2/hu unknown
- 2000-12-15 EP EP00986610A patent/EP1246832A1/en not_active Withdrawn
2002
- 2002-04-08 ZA ZA200202739A patent/ZA200202739B/en unknown
- 2002-06-13 NO NO20022816A patent/NO20022816L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
RU2002112248A (ru)	2004-01-20
NO20022816D0 (no)	2002-06-13
CN1409721A (zh)	2003-04-09
HRP20020486A2 (en)	2004-08-31
MXPA02006259A (es)	2003-01-28
KR20030016213A (ko)	2003-02-26
SI21042A (sl)	2003-04-30
US6518253B1 (en)	2003-02-11
HUP0400500A2 (hu)	2004-07-28
JP2003518134A (ja)	2003-06-03
CZ2002968A3 (cs)	2003-10-15
US20030092644A1 (en)	2003-05-15
PL356640A1 (pl)	2004-06-28
BR0016163A (pt)	2002-08-13
IL148510A0 (en)	2002-09-12
AU2281601A (en)	2001-07-03
HK1050011A1 (zh)	2003-06-06
CA2384110A1 (en)	2001-06-28
ZA200202739B (en)	2003-09-23
NO20022816L (no)	2002-06-13
EP1246832A1 (en)	2002-10-09
WO2001046212A1 (en)	2001-06-28
YU47702A (sh)	2005-11-28

Legal Events

Date	Code	Title	Description
2010-08-09	FC9A	Refused patent application

Publication	Publication Date	Title
RU2259831C2 (ru)	2005-09-10	Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием
US20040002596A1 (en)	2004-01-01	Nucleoside compounds and uses thereof
US6518253B1 (en)	2003-02-11	Treatment of viral infections using the L-isomer of ribavirin
SI20024A (sl)	2000-02-29	Purinovi L-nukleozidi, analogi in uporaba od teh
RU2073522C1 (ru)	1997-02-20	Лекарственный препарат противовирусного действия
SI9720013A (sl)	1999-06-30	Uravnavanje ekspresije citokinov TH1/TH2 z ribavirinom in z analogi ribavirina v aktiviranih T-limfocitih
JP2002527522A (ja)	2002-08-27	慢性Ｃ型肝炎感染を有する患者における検出可能ＨＣＶ−ＲＮＡ根絶用リバビリン−インターフェロン−α併用療法
USRE40882E1 (en)	2009-08-25	Antiviral nasal drops comprising recombinant interferon a biocompatible polymer and an antioxidant
US5824664A (en)	1998-10-20	Suppression of HIV expression by organic thiophosphate
JPH01501551A (ja)	1989-06-01	新規な医薬用途
RU2043767C1 (ru)	1995-09-20	Способ подавления вич-инфекции
SK10092001A3 (sk)	2002-02-05	Použitie nukleozidu ako liečiva na liečenie odpovede imunitného systému na expozíciu
JP2004035537A (ja)	2004-02-05	活性化ｔリンパ球におけるリバビリン及びリバビリン類似体によるｔｈ１型／ｔｈ２型サイトカインの発現の調節
EP0344643A2 (en)	1989-12-06	Antiviral pharmaceutical composition
US20050159372A1 (en)	2005-07-21	Nucleoside analogs with carboxamidine modified monocyclic base
UA73761C2 (uk)	2005-09-15	Карбоксамідин для лікування вірусного гепатиту